Incyte Corp SEC Filings

INCYTE CORP director Paul J. Clancy completed an option exercise and share sale. On May 19, 2026, he exercised non-qualified stock options to acquire 15,000 shares of common stock at $84.53 per share and sold 15,000 shares at $94.93 per share in an open-market transaction.

After these transactions, he directly owned 23,741 shares of common stock. This figure includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.

Stein Steven H reported acquisition or exercise transactions in this Form 4 filing.

Incyte Corp chief medical officer Steven H. Stein reported an amended insider transaction showing he earned 44,124 shares of common stock tied to performance shares. The compensation committee determined on May 6, 2026 that specified development, revenue and market-based goals had been achieved.

The earned shares will vest on the third anniversary of the July 14, 2023 grant date, as long as he continues serving the company. Including this certification, Stein now has 78,327 shares of common stock issuable from previously reported restricted stock units and earned performance shares that have not yet vested.

INCYTE CORP reported that President and Global Head of R&D Pablo J. Cagnoni acquired 31,517 shares of common stock through a grant of earned performance shares on May 6, 2026. These shares relate to performance criteria determined to be satisfied on that date and carry no purchase price.

The earned shares will vest on the third anniversary of the original July 14, 2023 grant date, if he continues serving the company. Over the three-year performance period, the number of shares he may receive ranges from 0% to 150% of the performance shares awarded, based on development, revenue and market-based goals tied to relative total shareholder returns versus the Nasdaq Biotechnology Index.

After this certification, Cagnoni holds 266,317 shares directly, including 261,178 shares of common stock issuable from previously reported restricted stock units and earned but unvested performance shares. This Form 4/A amends an earlier filing to reflect the Compensation Committee’s updated performance determination on May 6, 2026.

Incyte Corporation: Institutional ownership update. Dodge & Cox reports beneficial ownership of 12,252,356 shares of Incyte Corporation, representing 6.2% of the class. The filer reports sole voting power for 11,646,204 shares and sole dispositive power for 12,252,356 shares. The filing states these shares are held on behalf of Dodge & Cox clients.

Baker Bros. Advisors and related entities filed Amendment No. 33 to their Schedule 13D on Incyte, updating their beneficial ownership and recent option activity. The adviser and its GP report beneficial ownership of 30,865,077 Incyte shares, or 15.4% of the common stock, while Julian and Felix Baker each report beneficial ownership of just over 31.2 million shares, or 15.6% of the class.

The amendment reflects the adviser’s acquisition of 15,000 Incyte shares on May 8, 2026 through the exercise of options at $84.53 per share, for total consideration of $1,267,950. The options were held directly by Julian C. Baker in connection with his board service, but fund and adviser policies assign the economic benefit and investment power over these director compensation awards to the Baker Brothers funds.

To fund the exercise, the adviser drew $106,395 on a revolving note for Fund 667 and $1,161,555 on a separate revolving note for the Life Sciences fund. Both notes accrue interest at 4.62% per year and mature on May 1, 2053, or earlier if the acquired Incyte shares are sold. The filing reiterates that the Baker entities hold Incyte primarily for investment purposes and may increase or decrease their position over time, while currently stating no specific plans for extraordinary corporate transactions with the company.

INCYTE CORP insiders linked to Baker Bros. reported routine equity compensation activity. Entities associated with 667, L.P. and Baker Brothers Life Sciences LP exercised in total 30,000 non-qualified stock options at an exercise price of $84.53 per share, receiving the same number of Incyte common shares.

The options were originally granted to director Julian C. Baker for board service, but under advisory policies he has no direct pecuniary interest in these awards or the shares issued. The related funds and their affiliates instead hold indirect proportionate pecuniary interests, while Baker Bros. Advisors LP has voting and dispositive power over these securities.

After these exercises, the funds report indirect holdings of 28,203,718 and 2,833,039 Incyte shares, alongside direct holdings of 281,190 and 278,773 shares by Julian and Felix Baker and 33,410 shares held by FBB Associates. No open-market purchases or sales are disclosed in this filing.

INCYTE CORP executive vice president and chief financial officer Suketu Upadhyay received new equity awards as part of his compensation. He was granted 26,343 restricted stock units, vesting 25% annually over four years and settling one-for-one in common shares.

He also received 13,171 performance shares, which can deliver up to 200% of one common share each based on relative total shareholder return over a three-year period beginning January 1, 2026, with earned shares vesting on the third anniversary of the grant. In addition, he was granted 38,429 stock options with a $97.14 exercise price, vesting 25% after one year and the remainder in monthly installments over the next three years, and expiring on May 4, 2036.

INCYTE CORP executive Suketu Upadhyay, EVP & Chief Financial Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions, no derivative positions and no holding entries, making this a routine regulatory ownership registration for a new insider officer.